why choose us

First received: July 29, 2022

Clinical Trial: Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Study Status: Completed

Recruit Status: Completed

Condition: Pancreatic Cancer Resectable

Study Type: Observational


Official Title: Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study

Brief Summary: Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Read more